Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease

Abstract

Obesity is currently an epidemic, and the prevalence of cardiovascular risk factors is increasing dramatically as a result. Visceral adiposity is correlated with a proinflammatory and prothrombotic state that is believed to promote atherosclerosis and acute coronary syndromes. This article will review clinical trials on the effects of weight loss and pharmacotherapy on obesity associated inflammatory and thrombotic markers linked with cardiovascular disease.

Keywords::

• angiotensin-converting enzyme inhibitors
• angiotensin II Type I receptor blockers
• aspirin
• cardiovascular disease
• inflammation
• metabolic syndrome
• metformin
• obesity
• statins
• thiazolidinediones